Opendata, web and dolomites

TIR-C SIGNED

NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TIR-C project word cloud

Explore the words cloud of the TIR-C project. It provides you a very rough idea of what is the project "TIR-C" about.

contain    safety    diabetes    quality    affordable    symptom    clinical    clinicians    unsuitable    patients    itch    life    local    profile    commercialisation    costly    treatment    health    validate    ad    safe    rate    readiness    symptoms    damage    steroid    atopic    cream    contract    freedom    survey    persons    iia    approvals    80    expenditures    societies    conduct    tir    infected    plan    steroids    severe    eliminate    inflammation    sufferers    ab    economic    escalation    skin    therapy    formulation    biologics    action    regulatory    deprivation    consistently    blockbuster    lesions    burden    psychological    self    unresolved    administrated    drafted    entirely    anti    mind    manufacturing    poses    unmet    children    trials    sleep    works    excellent    extremely    confirm    pharma    feasibility    moderate    group    market    defences    disease    topical    dermatology    kols    pricing    immune    productivity    mild    cro    water    intravenously    communicated    vital    relives    consequently    prevent    operate    mechanism    patient    preparations    dermatitis    interfere    tirmed    enormous   

Project "TIR-C" data sheet

The following table provides information about the project.

Coordinator
TIRMED PHARMA AB 

Organization address
address: SPETS ALVIKSVAGEN 1
city: BROMMA
postcode: 16753
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TIRMED PHARMA AB SE (BROMMA) coordinator 50˙000.00

Map

 Project objective

TIRmed pharma AB has developed a non-steroid cream that relives itch in Atopic Dermatitis (AD). Itch is an enormous, unresolved symptom in AD, induced by inflammation and skin damage. AD poses a significant burden on societies and patients’ quality of life due to itch, infected lesions, sleep deprivation, and consequently productivity loss, psychological health and treatment-associated expenditures. Persons affected by AD consistently rate AD management to be comparable to diabetes management. Our TIR-C cream doesn’t contain steroids and works through an entirely novel mechanism of action. The therapy has been developed with the largest patient group in mind; children. TIR-C has the potential to become a blockbuster in AD management as it has an excellent safety profile, is very affordable, is easy to self-apply (water-based), doesn’t interfere with vital immune defences and has the potential to prevent disease escalation. We target mild-to-moderate symptoms (80% of all AD sufferers), aiming to eliminate the need for intravenously administrated biologics. Biologics are not only extremely costly, but also associated with severe side effects, making them unsuitable for children. The unmet need for safe, topical anti-itch-treatment in persons with mild-to-moderate AD has been clearly communicated by leading contract research organizations, KOLs and clinicians within dermatology. TIR-C is at Technology Readiness Level 4 with established manufacturing and formulation processes and a clinical development plan drafted in collaboration with a leading CRO in dermatology. The proposed feasibility study will advance preparations for commercialisation by allowing us to confirm regulatory requirements needed for market approvals, validate pricing through a health-economic survey in the EU, identify a local CRO to conduct the planned phase I/IIa clinical trials and confirm Freedom to Operate.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIR-C" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIR-C" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More  

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More